Get the Stockscreener App
0.8701
17.22%
0.1278
After Hours:
.87
-0.000100
-0.01%
Immunic Inc stock is traded at $0.8701, with a volume of 5.52M.
It is up +17.22% in the last 24 hours and up +31.53% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
See More
Previous Close:
$0.7423
Open:
$0.7548
24h Volume:
5.52M
Relative Volume:
3.49
Market Cap:
$104.66M
Revenue:
-
Net Income/Loss:
$-93.61M
P/E Ratio:
-0.4124
EPS:
-2.11
Net Cash Flow:
$-71.16M
1W Performance:
+47.72%
1M Performance:
+31.53%
6M Performance:
+2.10%
1Y Performance:
-7.24%
1-Day Range:
$0.7253
$0.894
1-Week Range:
$0.5801
$0.894
52-Week Range:
$0.5062
$1.39
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.8701 | 89.29M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Initiated | Roth Capital | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
Immunic showcases Phase 2 data on vidofludimus calcium at ACTRIMS Forum - Proactive financial news
HC Wainwright Reaffirms "Buy" Rating for Immunic (NASDAQ:IMUX) - MarketBeat
IMUX: HC Wainwright & Co. Reiterates Buy Rating with $8 Target | - GuruFocus
Is Immunic Inc attractive for institutional investorsInsider Buying & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Brookline Cap M Predicts Immunic FY2025 Earnings - MarketBeat
Immunic (NASDAQ:IMUX) Upgraded at Brookline Cap M - MarketBeat
Analysts Set Expectations for Immunic FY2025 Earnings - MarketBeat
Immunic (NASDAQ:IMUX) Upgraded at Brookline Capital Management - Defense World
Brookline Capital Management Upgrades Immunic (NASDAQ:IMUX) to "Strong-Buy" - MarketBeat
Immunic to present additional data on MS drug at ACTRIMS forum - Investing.com Nigeria
Small cap wrap: Fineqia, Immunic, M2i Global, Trust Stamp… - Proactive Investors
Immunic to present additional data on MS drug at ACTRIMS forum By Investing.com - Investing.com South Africa
Immunic to present additional Phase 2 data on vidofludimus calcium in progressive MS - Proactive financial news
MS trial: Immunic therapy cuts brain lesions and EBV signals - Stock Titan
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis - Sahm
Buyback Watch: Is Sandisk Corporation stock a top performer YTDPortfolio Gains Report & Target Return Focused Stock Picks - baoquankhu1.vn
Immunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Chipmakers Recap: Is Immunic Inc stock a good dividend stockJuly 2025 Reactions & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Fed Meeting: Is Immunic Inc stock a good dividend stockWeekly Market Outlook & AI Driven Price Forecasts - baoquankhu1.vn
Insider Traders Lose US$42k As Immunic Drops - simplywall.st
Immunic (NASDAQ:IMUX) Trading Down 2.1%Here's Why - MarketBeat
Published on: 2026-01-29 08:29:42 - baoquankhu1.vn
Buy Signal: Whats next for DRTSW stockWeekly Earnings Recap & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Aug Sentiment: Should value investors consider Immunic Inc2025 Earnings Surprises & Weekly High Return Stock Opportunities - baoquankhu1.vn
Published on: 2026-01-18 02:31:06 - baoquankhu1.vn
Market Recap: Whats next for Immunic Inc stockPortfolio Value Report & Real-Time Price Movement Reports - baoquankhu1.vn
Valuation Update: What is Immunic Incs book value per share2025 Earnings Surprises & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Aug Outlook: Can Immunic Inc stock maintain growth trajectoryEarnings Miss & Fast Gain Swing Alerts - Bộ Nội Vụ
Immunic (IMUX) Reviews 2025 Performance and Highlights Upcoming Milestones, Shares Up 24.10% - Finviz
Immunic targets MS market with Phase 3 dataICYMI - Proactive financial news
Published on: 2026-01-09 20:07:43 - ulpravda.ru
Can Immunic Inc. stock beat market expectations this quarterTrade Entry Report & AI Driven Stock Price Forecasts - Улправда
Earnings Update: Will Immunic Inc stock see insider buyingJuly 2025 Drop Watch & Consistent Income Trade Recommendations - Bộ Nội Vụ
How Immunic Inc. stock performs in high volatility marketsJuly 2025 Macro Moves & Weekly Hot Stock Watchlists - ulpravda.ru
Can Immunic Inc. stock maintain operating marginsJobs Report & Consistent Profit Trade Alerts - ulpravda.ru
Will Immunic Inc. stock see insider buyingJuly 2025 Volume & High Accuracy Investment Entry Signals - ulpravda.ru
Why Immunic Inc. (10VA) stock appears on watchlists2025 Buyback Activity & Long-Term Growth Portfolio Plans - ulpravda.ru
Will Immunic Inc. stock keep outperforming rivals2025 Growth vs Value & Reliable Entry Point Alerts - Улправда
Immunic (NASDAQ:IMUX) Given Buy Rating at D. Boral Capital - Defense World
D. Boral Capital Reaffirms Buy Rating for Immunic (NASDAQ:IMUX) - MarketBeat
IMUX: D. Boral Capital Maintains 'Buy' Rating with $8 Price Targ - GuruFocus
Immunic looks to 2026 data as late-stage MS program advances - Proactive financial news
Immunic CEO on key 2025 highlights and 2026 milestones - Proactive financial news
EQS-News: Immunic AG: Immunic Highlights 2025 Accomplishments and Upcoming Milestones - FinanzNachrichten.de
Immunic Highlights 2025 Accomplishments and Upcoming Milestones - PR Newswire
Immunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Immunic Transfers Listing to Nasdaq Capital Market for Compliance - TipRanks
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):